We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
AbbVie has completed its acquisition of Belgium-based Syndesi Therapeutics, broadening its neuroscience portfolio with several candidate drugs for treating a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer’s disease and major depressive disorder. Read More
Takeda Pharmaceuticals and Code Biotherapeutics are teaming up to develop gene therapies for treatment of rare diseases in a deal that is potentially worth up to $2 billion to Hatfield, Pa.-based Code Bio. Read More
Johnson & Johnson (J&J) has struck a deal with Remix Therapeutics — newly launched in late 2020 — to develop small-molecule therapeutics capable of reprogramming RNA processing for up to three disease targets in immunology and oncology. Read More
Merck and Curve Therapeutics have struck a collaboration pact potentially exceeding $1.7 billion to develop drugs for up to five disease targets in oncology and neurology. Read More
Lilly claimed bebtelovimab was shown to maintain neutralizing activity against the predominant Omicron variant and its more transmissible BA.2 subvariant. Read More
Pfizer’s COVID-19 vaccine racked up $36.8 billion in total sales in 2021, making it the single-highest annual sales total of any pharmaceutical product ever. Read More
The United Nations-backed Medicines Patent Pool (MPP) announced yesterday that it signed an agreement with Cape Town, South Africa-based Afrigen Biologics “to allow Afrigen to establish itself as the global mRNA vaccine technology transfer hub.” Read More